...Meghan E. Fredette; Sabitha Sasidharan Pillai; Osama Ibrahim; Manpreet Kochhar; Travis M. Cotton; Tanya O. Rogo; Margaret D. Scheffler; Andrew J. Bauer Introduction: Agranulocytosis is a rare but serious complication of methimazole (MMI) use for Graves’ disease (GD). Treatment requires...

... treated with antithyroid drugs (ATDs) for many years. Thus the majority of pediatric patients with GD will need thyroidectomy or treatment with radioactive iodine (RAI; 131 I). Results: When ATDs are used in children, only methimazole should be used. Propylthiouracil is associated with an unacceptable...

...’ patients after 6-12 months of methimazole treatment. ABRs remained abnormal in all the hypothyroid patients despite their having been on L -thyroxine treatment for 6-12 months and were euthyroid for at least 5 months before the study was repeated. These findings suggest that ABR abnormalities...

... with nodular or diffuse goiter were still hyperthyroid 6–9 months after discontinuation of the drug. The administration of high doses (40 mg/day) of methimazole alone proved to be ineffective in most (14/16) patients given this treatment. Twenty-seven patients were treated by methimazole combined...

...Angelica C. Vitug; Joel M. Goldman We review the cases of hepatic injury from propylthiouracil, methimazole and carbimazole in the English language literature and compare them to cases of agranulocytosis in a recent review. The data on hepatotoxicity confirm the findings for agranulocytosis...